Merck Millipore launched in Thailand, Advancing Life Science Together

Press Releases »

Bangkok--10 Mar--Merck Thailand

Merck Thailand, the local subsidiary of a Germany -- based pharmaceutical and chemical company, formally introduced Merck Millipore to its customers in Thailand as part of its plan to expand the growth opportunities in the Life Science Industry. Merck KGaA, the German parent company, acquired Millipore Corporation, a leading Life Science company based in Billerica, Massachusetts, USA, in July for approximately EUR 5.2 billion (US$7.0 billion). Since then Merck has been integrating its existing chemicals operations around the globe with those of Millipore. “With today’s launch of Merck Millipore, we are creating a world-class partner for the Life Science sector with a comprehensive product offering,” said Aman Bhattacharjee, Managing Director, Merck Thailand. “We will now move quickly to bring together the expertise and complementary capabilities of both Merck and Millipore talents to capture the significant opportunities in the high-growth and innovative offerings in segments such as bio-research and bio-production.” He further said, “Both Merck Chemicals and Millipore have a long and proud history of providing superior products and solutions to their partners in the Life Science sector. The increased breadth of the Merck Millipore product portfolio, together with the expertise of our talented people, will allow us to deepen our customer relationships and gain the new insights we need to further drive innovation. We will also bring together our research and development capabilities, which will make Merck Millipore one of the top three investors in R&D in the Life Science Tools industry. This, in turn, will enable us to create greater value for our customers.” Merck Thailand was jointly established in 1991 by Merck KGaA and B Grimm (Thailand). The establishment of the Thai company has been considered as a further expansion of the Merck Group. Merck Thailand has imported chemical and pharmaceutical products from Merck KGaA and its associated companies, supplied to hospitals, educational institutions and various industries in Thailand. Last year Merck Thailand generated about 2.0 billion baht in sales.

ข่าวMerck KGaA+o:conวันนี้

ลิกซิลร่วมฉลองความเป็นเลิศของแวดวงสถาปัตยกรรมและการออกแบบในงาน World Architecture Festival 2023

ลิกซิล โดยแบรนด์โกรเฮ่ สนับสนุน World Architecture Festival เป็นปีที่ 16 ติดต่อกัน พร้อมเปิดตัวผลิตภัณฑ์ GROHE SPA สำหรับภูมิภาค Asia Pacific ลิกซิล (LIXIL) ผู้บุกเบิกผลิตภัณฑ์เพื่อการจัดการน้ำและที่อยู่อาศัย มีความยินดีที่ได้สนับสนุน World Architecture Festival 2023 (WAF) ซึ่งจัดขึ้นเป็นครั้งที่ 16 ณ มาริน่า เบย์ แซนด์ส สิงคโปร์ ผ่านพาวเวอร์แบรนด์อย่างโกรเฮ่ โดยเทศกาล WAF เป็นการรวมตัวที่ใหญ่ที่สุดระดับโลกของเหล่าสถาปนิกและนักออกแบบ (A&D) ชั้นนำ รวมถึงบรรดาผู้นำทางความคิด อีกทั้ง

Merck KGaA, Darmstadt, Germany and p-Chip Corporation Collaborate to Improve Trust and Transparency in Machine-to-Machine Driven Industrial Value Chains

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and p-Chip Corporation, a company that is revolutionizing the tracking of...

Merck KGaA, Darmstadt, Germany: Driving Innovation in Cancer Care at ESMO 2017 With New Data in Hard-to-Treat Cancers

- Not intended for UK-based media - Data to showcase Merck KGaA, Darmstadt, Germany's strong and diverse pipeline ranging from immuno-oncology to DNA damage response - Avelumab data...

Merck KGaA, Darmstadt, Germany, Announces Recipients of Third Annual EUR 1 Million 'Grant for Oncology Innovation' Award

Not intended for UK-based media Grant established by Merck KGaA, Darmstadt, Germany, recognizes pioneering research in personalized treatment of solid tumors Winners selected by...

Merck KGaA, Darmstadt, Germany to Present New Research Focused on Hard-to-Treat Cancers at ESMO 2016

Not intended for UK-based media ESMO Abstract # Avelumab: 777PD, 7775PD, 1154P, 842TiP, 844TiP; Erbitux: 527P, 491P, 967P, 994P; Tepotinib: 1257P, 1287TiP, 1292TiP Merck KGaA, Darmstadt, Germany, to...

Mylan Completes Acquisition of Generics Business of Merck KGaA

Mylan (NYSE: MYL) announced today that it has completed its acquisition of Merck KGaA's generics business ("Merck Generics") to become one of the largest quality generics and specialty pharmaceuticals companies in the world. Mylan and...

Mylan Laboratories to Acquire Generics Business of Merck KGaA

Combination Creates a World Class Global Generics Leader Significant Scale and Breadth Will Drive Major Operating Efficiencies Highly Complementary Transaction Further Strengthens Mylan's Product Portfolio Accelerates Mylan's Revenue and...

Merck KGaA: Erbitux(R) (cetuximab) Continues to Deliver its Promise

Abstracts: 3085, 3509, 3535, 3549, 3555, 3556, 5537, 7109 Location: 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) 2006, Atlanta, Georgia Merck KGaA releases wealth of new Erbitux(R) (cetuximab) data at ASCO...